Reimbursed Care Access in Grenada

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Grenada’s Drug Abuse (Prevention and Control) Act (CAP 84A) provides the statutory framework for controlled psychotropic substances and does not create a legal medical/reimbursement pathway or explicit research carve-out for substances such as psilocybin. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public evidence of an established MDMA-assisted therapy program, special licensing scheme, or reimbursement pathway in Grenada. Grenada’s drug-control framework emphasizes control and prevention rather than establishing medical access for psychotropic/psychedelic drugs. #

Esketamine (intranasal Spravato®) is not known to be authorized, marketed, or reimbursed in Grenada; there is no public record of a national regulatory approval or a reimbursed access pathway. Grenada’s Drug Abuse (Prevention and Control) Act (CAP 84A) contains the national schedule structure and makes no provision for a psychoactive treatment programme analogous to those used for novel psychiatric medicines in some larger jurisdictions, and Grenada has not publicized a national approval for esketamine. # By contrast, esketamine has been approved and deployed with restricted REMS-type clinic requirements in other jurisdictions (for example, the U.S. FDA approval history for Spravato). This international approval does not imply Grenadian authorization or reimbursement. #

Ketamine is a recognised and widely used anaesthetic/analgesic in global clinical practice and is listed on the WHO Model List of Essential Medicines (injectable ketamine) for use in surgical and emergency settings; this supports its availability for standard anaesthetic indications in many countries, including small island health systems. #

In Grenada specifically, there is no public regulatory text establishing ketamine for formal, reimbursed psychiatric indications (e.g., treatment‑resistant depression). Ketamine will typically be available and used within hospital and emergency/operative medicine as an anaesthetic and analgesic under standard medical practice, but any use of ketamine for psychiatric indications would be off‑label, clinician‑driven, and would not have an established national reimbursement pathway separate from standard hospital funding. The national drug-control framework (Drug Abuse (Prevention and Control) Act CAP 84A) governs controlled substances and does not establish a reimbursed psychiatric ketamine programme, specialized certification, or nationwide funding for off‑label psychiatric ketamine administration. #

Operationally this means: (1) ketamine is medically available and used for anaesthesia/acute care in clinical settings; (2) ketamine-based psychiatric treatments (infusions, intranasal racemic ketamine from compounding pharmacies, etc.) — if provided at all — would be off-label private clinical practice with no documented public reimbursement framework in Grenada; and (3) any clinician-delivered psychiatric ketamine would require local hospital/clinic approvals and be subject to controlled-substances handling and importation rules under national law. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Grenada’s legislative framework does not provide for routine medical or reimbursed access to DMT-containing preparations (including simple possession or therapeutic access), and there are no published national programmes authorizing DMT therapy. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public regulatory pathway or reimbursement mechanism for 5‑MeO‑DMT in Grenada. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Grenada does not publish an established medical programme or reimbursement pathway for ibogaine-based addiction treatments. Any use would be outside the legal medical framework unless explicitly authorized in approved research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. While some jurisdictions provide religious exemptions for DMT‑containing brews, Grenada’s national law and policy framework do not indicate recognized legal exemptions or a regulated therapeutic programme for ayahuasca, nor a reimbursed clinical access pathway. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public record that mescaline (or mescaline‑containing cacti preparations) enjoys a medical exemption or reimbursement mechanism in Grenada. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Novel phenethylamines often fall squarely under the controlled/illicit category in Grenada and there is no authorized therapeutic or reimbursed access path for 2C‑class compounds. #